Correlation Between C4 Therapeutics and Passage Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both C4 Therapeutics and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining C4 Therapeutics and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between C4 Therapeutics and Passage Bio, you can compare the effects of market volatilities on C4 Therapeutics and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in C4 Therapeutics with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of C4 Therapeutics and Passage Bio.

Diversification Opportunities for C4 Therapeutics and Passage Bio

-0.04
  Correlation Coefficient

Good diversification

The 3 months correlation between CCCC and Passage is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding C4 Therapeutics and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and C4 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on C4 Therapeutics are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of C4 Therapeutics i.e., C4 Therapeutics and Passage Bio go up and down completely randomly.

Pair Corralation between C4 Therapeutics and Passage Bio

Given the investment horizon of 90 days C4 Therapeutics is expected to under-perform the Passage Bio. But the stock apears to be less risky and, when comparing its historical volatility, C4 Therapeutics is 2.06 times less risky than Passage Bio. The stock trades about -0.07 of its potential returns per unit of risk. The Passage Bio is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  66.00  in Passage Bio on November 2, 2024 and sell it today you would lose (8.00) from holding Passage Bio or give up 12.12% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

C4 Therapeutics  vs.  Passage Bio

 Performance 
       Timeline  
C4 Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Passage Bio 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Passage Bio are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Passage Bio reported solid returns over the last few months and may actually be approaching a breakup point.

C4 Therapeutics and Passage Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with C4 Therapeutics and Passage Bio

The main advantage of trading using opposite C4 Therapeutics and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if C4 Therapeutics position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.
The idea behind C4 Therapeutics and Passage Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.